Rachel Friedman Ohana

Dr. Rachel Friedman Ohana

Promega Corporation
orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2009 in Protein Expression and Purification
Verified
Journal Article
Closed access
Rachel Friedman OhanaRachel Friedman Ohana
Rachel Friedman Ohana
LELance P. Encell
Lance P. Encell
KZKate Zhao
Kate Zhao
DSDan Simpson
Dan Simpson
MSMichael R. Slater
Michael R. Slater
KWKeith V. Wood
Keith V. Wood

20 June 2020 in Annual Review of Biochemistry
Verified
Journal Article
Closed access
MRM.B. Robers
M.B. Robers
Rachel Friedman OhanaRachel Friedman Ohana
Rachel Friedman Ohana
KHK.V.M. Huber
K.V.M. Huber
LKLaura Kilpatrick
Laura Kilpatrick
JVJ.D. Vasta
J.D. Vasta
KWK.V. Wood
K.V. Wood
The binding affinity and kinetics of target engagement are fundamental to establishing structure–activity relationships (SARs) for prospective therapeutic agents. Enhancing these binding parameters for operative targets, while minimizing binding to off-target sites, can translate to improved drug efficacy and a widened therapeutic window. Compound activity is typically assessed through modulation of an observed phenotype in cultured cells. Quantifying the corresponding binding properties under common cellular conditions can provide more meaningful interpretation of the cellular SAR analysis. Consequently, methods for assessing drug binding in living cells have advanced and are now integral to medicinal chemistry workflows. In this review, we survey key technological advancements that support quantitative assessments of target occupancy in cultured cells, emphasizing generalizable methodologies able to deliver analytical precision that heretofore required reductionist biochemical approaches.

1 April 2020 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
MBMichelle Boursier
Michelle Boursier
SLSergiy Levin
Sergiy Levin
KZKris Zimmerman
Kris Zimmerman
TMThomas Machleidt
Thomas Machleidt
RHRobin Hurst
Robin Hurst
Rachel Friedman OhanaRachel Friedman Ohana
Rachel Friedman Ohana
G protein–coupled receptors (GPCRs) are prominent targets to new therapeutics for a range of diseases. Comprehensive assessments of their cellular interactions with bioactive compounds, particularly in a kinetic format, are imperative to the development of drugs with improved efficacy. Hence, we developed complementary cellular assays that enable equilibrium and real-time analyses of GPCR ligand engagement and consequent activation, measured as receptor internalization. These assays utilize GPCRs genetically fused to an N-terminal HiBiT peptide (1.3 kDa), which produces bright luminescence upon high-affinity complementation with LgBiT, an 18-kDa subunit derived from NanoLuc. The cell impermeability of LgBiT limits signal detection to the cell surface and enables measurements of ligand-induced internalization through changes in cell-surface receptor density. In addition, bioluminescent resonance energy transfer is used to quantify dynamic interactions between ligands and their cognate HiBiT-tagged GPCRs through competitive binding with fluorescent tracers. The sensitivity and dynamic range of these assays benefit from the specificity of bioluminescent resonance energy transfer and the high signal intensity of HiBiT/LgBiT without background luminescence from receptors present in intracellular compartments. These features allow analyses of challenging interactions having low selectivity or affinity and enable studies using endogenously tagged receptors. Using the β-adrenergic receptor family as a model, we demonstrate the versatility of these assays by utilizing the same HiBiT construct in analyses of multiple aspects of GPCR pharmacology. We anticipate that this combination of target engagement and proximal functional readout will prove useful to the study of other GPCR families and the development of new therapeutics.

1 April 2011 in Protein Expression and Purification
Verified
Journal Article
Closed access
Rachel Friedman OhanaRachel Friedman Ohana
Rachel Friedman Ohana
RHRobin Hurst
Robin Hurst
JVJolanta Vidugiriene
Jolanta Vidugiriene
MSMichael R. Slater
Michael R. Slater
KWKeith V. Wood
Keith V. Wood
MUMarjeta Urh
Marjeta Urh

6 August 2015 in ACS Chemical Biology
Verified
Journal Article
Open access
Rachel Friedman OhanaRachel Friedman Ohana
Rachel Friedman Ohana
TKThomas A. Kirkland
Thomas A. Kirkland
CWCarolyn C. Woodroofe
Carolyn C. Woodroofe
SLSergiy Levin
Sergiy Levin
HUH. Tetsuo Uyeda
H. Tetsuo Uyeda
KWKeith V. Wood
Keith V. Wood
Phenotypic screening of compound libraries is a significant trend in drug discovery, yet success can be hindered by difficulties in identifying the underlying cellular targets. Current approaches rely on tethering bioactive compounds to a capture tag or surface to allow selective enrichment of interacting proteins for subsequent identification by mass spectrometry. Such methods are often constrained by ineffective capture of low affinity and low abundance targets. In addition, these methods are often not compatible with living cells and therefore cannot be used to verify the pharmacological activity of the tethered compounds. We have developed a novel chloroalkane capture tag that minimally affects compound potency in cultured cells, allowing binding interactions with the targets to occur under conditions relevant to the desired cellular phenotype. Subsequent isolation of the interacting targets is achieved through rapid lysis and capture onto immobilized HaloTag protein. Exchanging the chloroalkane tag for a fluorophore, the putative targets identified by mass spectrometry can be verified for direct binding to the compound through resonance energy transfer. Using the interaction between histone deacetylases (HDACs) and the inhibitor, Vorinostat (SAHA), as a model system, we were able to identify and verify all the known HDAC targets of SAHA as well as two previously undescribed targets, ADO and CPPED1. The discovery of ADO as a target may provide mechanistic insight into a reported connection between SAHA and Huntington’s disease.

3 August 2016 in ACS Chemical Biology
Verified
Journal Article
Open access
Rachel Friedman OhanaRachel Friedman Ohana
Rachel Friedman Ohana
SLSergiy Levin
Sergiy Levin
MWMonika G. Wood
Monika G. Wood
KZKris Zimmerman
Kris Zimmerman
MDMelanie L. Dart
Melanie L. Dart
KWKeith V. Wood
Keith V. Wood
The benefits provided by phenotypic screening of compound libraries are often countered by difficulties in identifying the underlying cellular targets. We recently described a new approach utilizing a chloroalkane capture tag, which can be chemically attached to bioactive compounds to facilitate the isolation of their respective targets for subsequent identification by mass spectrometry. The tag minimally affects compound potency and membrane permeability, enabling target engagement inside cells. Effective enrichment of these targets is achieved through selectivity in both their rapid capture onto immobilized HaloTag and their subsequent release by competitive elution. Here, we describe a significant improvement to this method where selective elution was achieved through palladium-catalyzed cleavage of an allyl-carbamate linkage incorporated into the chloroalkane capture tag. Selective tag cleavage provided robust release of captured targets exhibiting different modes of binding to the bioactive compound, including prolonged residence time and covalent interactions. Using the kinase inhibitors ibrutinib and BIRB796 as model compounds, we demonstrated the capability of this new method to identify both expected targets and “off-targets” exhibiting a range of binding affinities, cellular abundances, and binding characteristics.